|
1
|
López JI: Renal tumors with clear cells. A
review Pathol Res Pract. 209:137–146. 2013.
|
|
2
|
Ohba K, Miyata Y, Yasuda T, Asai A,
Mitsunari K, Matsuo T, Mochizuki Y, Matsunaga N and Sakai H:
Efficacy and safety of sunitinib alternate day regimen in patients
with metastatic renal cell carcinoma in Japan: Comparison with
standard 4/2 schedule. Asia Pac J Clin Oncol. 14:153–158. 2018.
|
|
3
|
Yang F, Zhou X, Du S, Zhao Y, Ren W, Deng
Q, Wang F and Yuan J: LIM and SH3 domain protein 1 (LASP-1)
overexpression was associated with aggressive phenotype and poor
prognosis in clear cell renal cell cancer. PLoS One.
9:e1005572014.
|
|
4
|
Teng J, Gao Y, Chen M, Wang K, Cui X, Liu
Y and Xu D: Prognostic value of clinical and pathological factors
for surgically treated localized clear cell renal cell carcinoma.
Chin Med J (Engl). 127:1640–1644. 2014.
|
|
5
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008.
|
|
6
|
Yoshino H, Nohata N, Miyamoto K, Yonemori
M, Sakaguchi T, Sugita S, Itesako T, Kofuji S, Nakagawa M, Dahiya
R, et al: PHGDH as a key enzyme for serine biosynthesis in
HIF2alpha targeting therapy for renal cell carcinoma. Cancer Res.
77:6321–6329. 2017.
|
|
7
|
Rajan A, Kim C, Heery CR, Guha U and
Gulley JL: Nivolumab, anti-programmed death-1 (PD-1) monoclonal
antibody immunotherapy: Role in advanced cancers. Hum Vaccin
Immunother. 12:2219–2231. 2016.
|
|
8
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al CheckMate 025 Investigators: Nivolumab versus
Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.
373:1803–1813. 2015.
|
|
9
|
Sarfaty M, Leshno M, Gordon N, Moore A,
Neiman V, Rosenbaum E and Goldstein DA: Cost Effectiveness of
Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. 73:628–634.
2018.
|
|
10
|
Carthew RW and Sontheimer EJ: Origins and
Mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
|
|
11
|
Landgraf P, Rusu M, Sheridan R, Sewer A,
Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M,
et al: A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell. 129:1401–1414. 2007.
|
|
12
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39(Database): D152–D157. 2011.
|
|
13
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836.
2012.
|
|
14
|
Xie M, Dart DA, Guo T, Xing XF, Cheng XJ,
Du H, Jiang WG, Wen XZ and Ji JF: MicroRNA-1 acts as a tumor
suppressor microRNA by inhibiting angiogenesis-related growth
factors in human gastric cancer. Gastric cancer. 21:41–54.
2018.
|
|
15
|
Xu W, Zhang Z, Zou K, Cheng Y, Yang M,
Chen H, Wang H, Zhao J, Chen P, He L, et al: MiR-1 suppresses tumor
cell proliferation in colorectal cancer by inhibition of
Smad3-mediated tumor glycolysis. Cell Death Dis. 8:e27612017.
|
|
16
|
Xi Y: MicroRNA: A New Player for Cancer
Chemoprevention. J Integr Oncol. 2:pii: 1052013.
|
|
17
|
Yi B, Piazza GA, Su X and Xi Y: MicroRNA
and cancer chemo-prevention. Cancer Prev Res (Phila). 6:401–409.
2013.
|
|
18
|
Lin HM, Nikolic I, Yang J, Castillo L,
Deng N, Chan CL, Yeung NK, Dodson E, Elsworth B, Spielman C, et al:
MicroRNAs as potential therapeutics to enhance chemosensitivity in
advanced prostate cancer. Sci Rep. 8:78202018.
|
|
19
|
Xiao W, Lou N, Ruan H, Bao L, Xiong Z,
Yuan C, Tong J, Xu G, Zhou Y, Qu Y, et al: Mir-144-3p Promotes Cell
Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal
Cell Carcinoma by Downregulating ARID1A. Cell Physiol Biochem.
43:2420–2433. 2017.
|
|
20
|
Sobin LH and Compton CC: TNM seventh
edition: what’s new, what’s changed: communication from the
International Union Against Cancer and the American Joint Committee
on Cancer. Cancer. 116:5336–5339. 2010.
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
22
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K, et al: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009.
|
|
23
|
Matsushita R, Yoshino H, Enokida H, Goto
Y, Miyamoto K, Yonemori M, Inoguchi S, Nakagawa M and Seki N:
Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145
(miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell
aggressiveness. Oncotarget. 7:28460–28487. 2016.
|
|
24
|
Yoshino H, Enokida H, Itesako T, Kojima S,
Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M and Seki N:
Tumor-suppressive microRNA-143/145 cluster targets hexo-kinase-2 in
renal cell carcinoma. Cancer Sci. 104:1567–1574. 2013.
|
|
25
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976.
|
|
26
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
|
|
27
|
Anaya J: OncoLnc: linking TCGA survival
data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science.
2:e672016.
|
|
28
|
Berkers J, Govaere O, Wolter P, Beuselinck
B, Schöffski P, van Kempen LC, Albersen M, Van den Oord J, Roskams
T, Swinnen J, et al: A possible role for microRNA-141
down-regulation in sunitinib resistant metastatic clear cell renal
cell carcinoma through induction of epithelial-to-mesenchymal
transition and hypoxia resistance. J Urol. 189:1930–1938. 2013.
|
|
29
|
Papadopoulos EI, Yousef GM and Scorilas A:
Cytotoxic activity of sunitinib and everolimus in Caki-1 renal
cancer cells is accompanied by modulations in the expression of
apoptosis-related microRNA clusters and BCL2 family genes. Biomed
Pharmacother. 70:33–40. 2015.
|
|
30
|
Goto Y, Kurozumi A, Nohata N, Kojima S,
Matsushita R, Yoshino H, Yamazaki K, Ishida Y, Ichikawa T, Naya Y,
et al: The microRNA signature of patients with sunitinib failure:
Regulation of UHRF1 pathways by microRNA-101 in renal cell
carcinoma. Oncotarget. 7:59070–59086. 2016.
|
|
31
|
Merhautova J, Hezova R, Poprach A,
Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R and Slaby O:
miR-155 and miR-484 Are Associated with Time to Progression in
Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Res
Int. 2015:9419802015.
|
|
32
|
Elford HL, Freese M, Passamani E and
Morris HP: Ribonucleotide reductase and cell proliferation I
Variations of ribonucleotide reductase activity with tumor growth
rate in a series of rat hepatomas. J Biol Chem. 245:5228–5233.
1970.
|
|
33
|
Elford HL, Wampler GL and van’t Riet B:
New ribonucleotide reductase inhibitors with antineoplastic
activity. Cancer Res. 39:844–851. 1979.
|
|
34
|
Elford HL, Van’t Riet B, Wampler GL, Lin
AL and Elford RM: Regulation of ribonucleotide reductase in
mammalian cells by chemotherapeutic agents. Adv Enzyme Regul.
19:151–168. 1980.
|
|
35
|
van’t Riet B, Wampler GL and Elford HL:
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids:
Inhibition of ribonucleotide reductase and antitumor activity. J
Med Chem. 22:589–592. 1979.
|
|
36
|
Chendrimada TP, Finn KJ, Ji X, Baillat D,
Gregory RI, Liebhaber SA, Pasquinelli AE and Shiekhattar R:
MicroRNA silencing through RISC recruitment of eIF6. Nature.
447:823–828. 2007.
|
|
37
|
Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X,
Zheng L, Xue Z, Xia W, Zhang B, et al: MicroRNA-99a induces
G1-phase cell cycle arrest and suppresses tumorigenicity in renal
cell carcinoma. BMC Cancer. 12:5462012.
|
|
38
|
Pink RC, Samuel P, Massa D, Caley DP,
Brooks SA and Carter DR: The passenger strand, miR-21-3p, plays a
role in mediating cisplatin resistance in ovarian cancer cells.
Gynecol Oncol. 137:143–151. 2015.
|
|
39
|
Ayers D and Vandesompele J: Influence of
microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. Genes
(Basel). 8:82017.
|
|
40
|
An X, Sarmiento C, Tan T and Zhu H:
Regulation of multidrug resistance by microRNAs in anti-cancer
therapy. Acta Pharm Sin B. 7:38–51. 2017.
|
|
41
|
Yumioka T, Osaki M, Sasaki R, Yamaguchi N,
Onuma K, Iwamoto H, Morizane S, Honda M, Takenaka A and Okada F:
Lysosome-associated membrane protein 2 (LAMP-2) expression induced
by miR-194-5p downregulation contributes to sunitinib resistance in
human renal cell carcinoma cells. Oncol Lett. 15:893–900. 2018.
|
|
42
|
Kishikawa T, Otsuka M, Tan PS, Ohno M, Sun
X, Yoshikawa T, Shibata C, Takata A, Kojima K, Takehana K, et al:
Decreased miR122 in hepatocellular carcinoma leads to
chemoresistance with increased arginine. Oncotarget. 6:8339–8352.
2015.
|
|
43
|
Arai T, Okato A, Yamada Y, Sugawara S,
Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits
cancer cell aggressiveness and is involved in CRPC. Cancer Med.
7:1988–2002. 2018.
|
|
44
|
Molina-Pinelo S, Carnero A, Rivera F,
Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor
MD, Chaves M, et al: MiR-107 and miR-99a-3p predict chemotherapy
response in patients with advanced colorectal cancer. BMC Cancer.
14:6562014.
|
|
45
|
Grolmusz VK, Karászi K, Micsik T, Tóth EA,
Mészáros K, Karvaly G, Barna G, Szabó PM, Baghy K, Matkó J, et al:
Cell cycle dependent RRM2 may serve as proliferation marker and
pharmaceutical target in adrenocortical cancer. Am J Cancer Res.
6:2041–2053. 2016.
|
|
46
|
Kang W, Tong JH, Chan AW, Zhao J, Wang S,
Dong Y, Sin FM, Yeung S, Cheng AS, Yu J, et al: Targeting
ribonucleotide reductase M2 subunit by small interfering RNA exerts
anti-oncogenic effects in gastric adenocarcinoma. Oncol Rep.
31:2579–2586. 2014.
|
|
47
|
Shah KN, Mehta KR, Peterson D, Evangelista
M, Livesey JC and Faridi JS: AKT-induced tamoxifen resistance is
overturned by RRM2 inhibition. Mol Cancer Res. 12:394–407.
2014.
|
|
48
|
Zuckerman JE, Hsueh T, Koya RC, Davis ME
and Ribas A: siRNA knockdown of ribonucleotide reductase inhibits
melanoma cell line proliferation alone or synergistically with
temozolomide. J Invest Dermatol. 131:453–460. 2011.
|
|
49
|
Liu X, Zhang H, Lai L, Wang X, Loera S,
Xue L, He H, Zhang K, Hu S, Huang Y, et al: Ribonucleotide
reductase small subunit M2 serves as a prognostic biomarker and
predicts poor survival of colorectal cancers. Clin Sci (Lond).
124:567–578. 2013.
|
|
50
|
Mah V, Alavi M, Márquez-Garbán DC, Maresh
EL, Kim SR, Horvath S, Bagryanova L, Huerta-Yepez S, Chia D,
Pietras R, et al: Ribonucleotide reductase subunit M2 predicts
survival in subgroups of patients with non-small cell lung
carcinoma: Effects of gender and smoking status. PLoS One.
10:e01276002015.
|
|
51
|
Fan H, Villegas C and Wright JA:
Ribonucleotide reductase R2 component is a novel malignancy
determinant that cooperates with activated oncogenes to determine
transformation and malignant potential. Proc Natl Acad Sci USA.
93:14036–14040. 1996.
|
|
52
|
Avolio TM, Lee Y, Feng N, Xiong K, Jin H,
Wang M, Vassilakos A, Wright J and Young A: RNA interference
targeting the R2 subunit of ribonucleotide reductase inhibits
growth of tumor cells in vitro and in vivo. Anticancer Drugs.
18:377–388. 2007.
|
|
53
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer’s Achilles’ heel. Cancer Cell. 13:472–482.
2008.
|
|
54
|
Vander Heiden MG: Targeting cancer
metabolism: A therapeutic window opens. Nat Rev Drug Discov.
10:671–684. 2011.
|
|
55
|
Lai IL, Chou CC, Lai PT, Fang CS, Shirley
LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, et al:
Targeting the Warburg effect with a novel glucose transporter
inhibitor to overcome gemcitabine resistance in pancreatic cancer
cells. Carcinogenesis. 35:2203–2213. 2014.
|
|
56
|
Liu J, Pan C, Guo L, Wu M, Guo J, Peng S,
Wu Q and Zuo Q: A new mechanism of trastuzumab resistance in
gastric cancer: MACC1 promotes the Warburg effect via activation of
the PI3K/AKT signaling pathway. J Hematol Oncol. 9:762016.
|
|
57
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Yamada Y, Tatarano S, Hidaka H, Yonezawa T, Nakagawa M and Enokida
H: Tumor-suppressive microRNA-1291 directly regulates glucose
transporter 1 in renal cell carcinoma. Cancer Sci. 104:1411–1419.
2013.
|
|
58
|
Wang N, Zhan T, Ke T, Huang X, Ke D, Wang
Q and Li H: Increased expression of RRM2 by human papillomavirus E7
oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer.
110:1034–1044. 2014.
|
|
59
|
Shah KN, Wilson EA, Malla R, Elford HL and
Faridi JS: Targeting Ribonucleotide Reductase M2 and NF-κB
Activation with Didox to Circumvent Tamoxifen Resistance in Breast
Cancer. Mol Cancer Ther. 14:2411–2421. 2015.
|
|
60
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009.
|
|
61
|
Putluri N, Maity S, Kommagani R, Creighton
CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T,
et al: Pathway-centric integrative analysis identifies RRM2 as a
prognostic marker in breast cancer associated with poor survival
and tamoxifen resistance. Neoplasia. 16:390–402. 2014.
|
|
62
|
Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J,
Gaur S, Smith DL, Yuan YC, Synold TW, et al: A small-molecule
blocking ribo-nucleotide reductase holoenzyme formation inhibits
cancer cell growth and overcomes drug resistance. Cancer Res.
73:6484–6493. 2013.
|
|
63
|
Zhang M, Wang J, Yao R and Wang L: Small
interfering RNA (siRNA)-mediated silencing of the M2 subunit of
ribonucleotide reductase: a novel therapeutic strategy in ovarian
cancer. Int G Gynecol Cancer. 23:659–666. 2013.
|
